Repligen Corporation - Common Stock — 현금 흐름 (NASDAQ:RGEN)

Financials

영업활동으로 인한 현금 62.63 M119.02 M172.08 M113.92 M175.39 M117.42 M 130.71 M 투자 활동으로 인한 현금 -201.38 M-221.17 M-233.24 M-123.28 M-86.38 M-298.47 M -228.35 M 재무활동으로 인한 현금 305.92 M961 K-13.34 M248.96 M-82.9 M-15.21 M -15.72 M 잉여 현금 흐름 62.63 M119.02 M172.08 M113.92 M175.39 M91.69 M 104.46 M

Repligen Corporation - Common Stock

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.

RGEN

Financials

Repligen Corporation - Common Stock

뉴스

Alger Mid Cap 40 ETF Q1 2026 Portfolio Movers

Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises

Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates

Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Alger Mid Cap Growth Fund Q1 2026 Portfolio Review

Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for

Conestoga Capital Small Cap Portfolio Quarterly Scorecard: Buys, Sells, And Standouts

Repligen: Advancing, Yet Much More Work Ahead (NASDAQ:RGEN)

Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?

Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Repligen, Leerink 컨퍼런스: 전략적 성장 및 과제

Repligen at Leerink Conference: Strategic Growth and Challenges